MED12 and Miyoshi myopathy: Altogether, these data indicate that pharmacologic inhibition of CDK8/19 in MM SCs effectively models gene expression changes in patient-derived MED12-mutant UFs, and further supports the notion that disruption of Mediator kinase activity contributes prominently to the molecular pathogenesis of MED12-mutant tumors.